GILD - Update On NASH Antifibrotics: Allergan Gilead Conatus Galectin
Previously, I analyzed the NASH cirrhosis space from a scientific perspective, comparing and contrasting the antifibrotic drugs Selonsertib (GILD), Emricasan (CNAT), and GR-MD-02 (GALT), whichwas recently assigned the USAN name belapectin. In retrospect, Allergan’s (AGN) cenicriviroc, a dual CCR2/CCR5 inhibitor that helps downregulate the production of cytokines that turn hepatic stellate cells into myofibroblasts, among other mechanisms, should have been included in the analysis. But, the scientific perspective of the true antifibrotic competing drugs (not metabolic drugs that claim to have secondary effects on early stage